Cytochrome p450 2C enzymes contribute to peritransplant ischemic injury and cardiac allograft vasculopathy

American Journal of Transplantation

Volumn 8, Issue 8, 2008, Pages 1631-1638

  Hunter, A L ^a   Kerjner, A ^a   Mueller, K J ^a   McManus, B M ^a   Granville, D J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiac allograft vasculopathy; Cyto chrome p450; Ischemia and repurfusion; Peritransplant injury

Indexed keywords

CYTOCHROME P450 2C; SULFAPHENAZOLE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY BLOOD VESSEL; ENZYME INHIBITION; HEART TRANSPLANTATION; ISCHEMIA; MALE; NICK END LABELING; NONHUMAN; PERIOPERATIVE COMPLICATION; PERIOPERATIVE PERIOD; PERITRANSPLANT ISCHEMIA; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SMOOTH MUSCLE FIBER;

ANIMALS; ANTI-INFECTIVE AGENTS; CELL PROLIFERATION; CORONARY VESSELS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HEART TRANSPLANTATION; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, INBRED LEW; SULFAPHENAZOLE; TRANSPLANTATION, HOMOLOGOUS;

EID: 48349115519     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02296.x     Document Type: Article

References (32)

1. Dong C, Granville DJ, Tuffnel CE et al. Bax and apoptosis in acute and chronic rejection of rat cardiac allografts. Lab Invest 1999 79 : 1643 1653.
2. Yeung AC, Davis SF, Hauptman PJ et al. Incidence and progression of transplant coronary artery disease over 1 year: Results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. J Heart Lung Transplant 1995 14 (6 Pt 2 S215 S220.
3. Wilhelm MJ, Kusaka M, Pratschke J, Tilney NL. Chronic rejection: Increasing evidence for the importance of allogen-independent factors. Transplant Proc 1998 30 : 2402 2406.
4. Laskowski I, Pratschke J, Wilhelm MJ, Gasser M, Tilney NL. Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transplant 2000 5 : 29 35.
5. Valantine HA. Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant atheroma Transplantation 2003 76 : 891 899.
6. Day JD, Rayburn BK, Gaudin PB et al. Cardiac allograft vasculopathy: The central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995 14 (6 Pt 2 S142 S149.
7. Schneeberger H, Schleibner S, Illner WD, Messmer K, Land W. The impact of free radical-mediated reperfusion injury on acute and chronic rejection events following cadaveric renal transplantation. Clin Transpl 1993 : 219 232.
8. Tilney NL, Paz D, Ames J, Gasser M, Laskowski I, Hancock WW. Ischemia-reperfusion injury. Transplant Proc 2001 33 : 843 844.
9. Waaga AM, Gasser M, Laskowski I, Tilney NL. Mechanisms of chronic rejection. Curr Opin Immunol 2000 12 : 517 521.
10. Kim J, Kil IS, Seok YM et al. Orchiectomy attenuates post-ischemic oxidative stress and ischemia/reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol Chem 2006 281 : 20349 20356.
11. Murata S, Miniati DN, Kown MH et al. Superoxide dismutase mimetic m40401 reduces ischemia-reperfusion injury and graft coronary artery disease in rodent cardiac allografts. Transplantation 2004 78 : 1166 1171.
12. Tanaka M, Mokhtari GK, Terry RD et al. Overexpression of human copper/zinc superoxide dismutase (SOD1) suppresses ischemia-reperfusion injury and subsequent development of graft coronary artery disease in murine cardiac grafts. Circulation 2004 110 (11 Suppl 1 II200 II206.
13. Nelson SK, Gao B, Bose S, Rizeq M, McCord JM. A novel heparin-binding, human chimeric, superoxide dismutase improves myocardial preservation and protects from ischemia-reperfusion injury. J Heart Lung Transplant 2002 21 : 1296 1303.
14. Yin M, Wheeler MD, Connor HD et al. Cu/Zn-superoxide dismutase gene attenuates ischemia-reperfusion injury in the rat kidney. J Am Soc Nephrol 2001 12 : 2691 2700.
15. Abunasra HJ, Smolenski RT, Morrison K et al. Efficacy of adenoviral gene transfer with manganese superoxide dismutase and endothelial nitric oxide synthase in reducing ischemia and reperfusion injury. Eur J Cardiothorac Surg 2001 20 : 153 158.
16. Wang X, Zuckerman B, Pearson C et al. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA 2002 287 : 195 202.
17. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 2002 162 : 391 397.
18. Fleming I, Michaelis UR, Bredenkotter D et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001 88 : 44 51.
19. Fisslthaler B, Popp R, Kiss L et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999 401 : 493 497.
20. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004 109 : 178 183.
21. Granville DJ, Tashakkor B, Takeuchi C et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci USA 2004 101 : 1321 1326.
22. Yasar U, Bennet AM, Eliasson E et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003 13 : 715 720.
23. Wu S, Chen W, Murphy E et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997 272 : 12551 12559.
24. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996 271 : 3460 3468.
25. Hunter AL, Bai N, Laher I, Granville DJ. Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction. Vascul Pharmacol 2005 43 : 213 219.
26. Kobayashi K, Urashima K, Shimada N, Chiba K. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat. Drug Metab Dispos 2003 31 : 833 836.
27. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: Studies in the Lewis-F344 model. Immunol Rev 1993 134 : 5 19.
28. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF. Nitric oxide modulates expression of cell cycle regulatory proteins: A cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 2000 101 : 1982 1989.
29. Ruiz E, Del Rio M, Somoza B, Ganado P, Sanz M, Tejerina T. L-Citrulline, the by-product of nitric oxide synthesis, decreases vascular smooth muscle cell proliferation. J Pharmacol Exp Ther 1999 290 : 310 313.
30. Janssens S, Flaherty D, Nong Z et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 1998 97 : 1274 1281.
31. Stein CS, Fabry Z, Murphy S, Hart MN. Involvement of nitric oxide in IFN-gamma-mediated reduction of microvessel smooth muscle cell proliferation. Mol Immunol 1995 32 : 965 973.
32. Wang Y, Bai Y, Qin L et al. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res 2007 101 : 560 569.